Pharmaceuticals

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

A new partnership between AGEPHA Pharma and Close-Up Intl reveals how AI is not just a buzzword, but a critical tool for getting vital medicines to patients.

Nippon Shinyaku and Boston Children's Hospital deepen their pact, combining corporate might with research prowess to create new therapies for rare neurology.

HLS Therapeutics is betting on itself with a larger share buyback. We analyze if this is a signal of deep value or a sign of limited growth opportunities.

Insmed recruits J&J and Novartis veteran Samuele Butera to execute the multi-billion-dollar launch of BRINSUPRI and expand its respiratory franchise.

A biopharma firm's celebrated 20% growth is now alleged to be a mirage, sparking a fraud lawsuit that questions where the line is drawn between ambition and accountability.

A new survey reveals the crippling cost of insulin, forcing millions to choose between medicine and groceries. A bipartisan bill may offer a lifeline.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The European Commission has approved MAVIRET for acute Hepatitis C, a move set to streamline patient care and accelerate progress against a silent epidemic.

AbbVie's blockbuster SKYRIZI wins European approval for pediatric psoriasis, unlocking a new market and offering a new standard of care to young patients.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

Cosmos Health secures 25M+ unit orders, projecting a $10M profit from its Greek facility. A bold manufacturing play to stabilize its finances.

With a new brand and $1B in state funding, Indiana is unifying its massive bioscience sector to challenge global hubs like Boston. Is 'BioHeartland' the real deal?

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

A decade of new science has prompted the FDA to overhaul testosterone therapy rules, erasing old fears and unlocking a multi-billion dollar market for aging men.

A new pharma deal isn't just about medicine. It's about the AI-driven network set to dismantle the slow, costly system of drug discovery as we know it.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.